To promote safety and wellness among U.S. travelers through the collection and dissemination of up-to-date and accurate scientific information.

To leverage the WHO Global Rotavirus Surveillance Network (GRSN) by using novel technology to achieve a better understanding of the role of enteric pathogens other than rotavirus in childhood diarrhea requiring hospitalization and create the Global Pediatric Diarrheal Surveillance Network (GPDS).

To honor and recognize important work to promote safe injection practices and patient safety and produce educational materials that raise awareness and highlight the work of the One & Only Campaign.

To support the production and qualification of inactivated rotavirus vaccine clinical material.

To develop a Global Pediatric Norovirus Laboratory Surveillance Network to monitor norovirus strains and provide data critical for decision-making related to norovirus vaccination.

To support two annual two-day conferences for journalists from media outlets reaching rural, frontier and urban populations to provide training on where to access reliable health information.

To show the health impact of low-cost, Indian-made rotavirus vaccines in high burden, low-income countries of Africa and Asia.

To support Haiti's vaccine distribution efforts as well as water and sanitation improvements in response to the 2021 earthquake.

To screen a subset of human and mouse monoclonal antibodies for their ability to neutralize GI.1; a time ordered panel of GII.4; and GII.3 noroviruses using a novel human intestinal enteroid cell culture system.

To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.

To develop cell culture and small animal models of Nipah virus replication and pathogenesis in a biosafety level (BSL) 4 lab.

To investigate long-acting PrEP formulations in macaque subjects.

To engage partners and stakeholders on awareness and education for infection associated chronic conditions (IACC).

To engage communities through the power of arts and culture to educate, empower and mobilize individuals toward positive change. Thriving Together Atlanta serves as a model of how cross-sector partnerships can address multifaceted issues affecting communities today.

To investigate the biocompatibility, the drug release profile and length of prophylactic efficacy of a biodegradable subcutaneous implant containing antiretroviral drug(s), developed by RTI.

To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners’ Engagement Framework.

To evaluate the safety, pharmacokinetics and efficacy of macaque-sized CLIP 3D printed intravaginal rings (IVRs) loaded with the potent antiretroviral Islatravir (EFdA) when administered vaginally to pigtailed macaques.

To support the introduction of a change in Burkina Faso’s infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country’s capacity to control pneumococcal disease among children and adults.

To support implementation of a set of recommendations and a roadmap developed in the "Strengthening Public Health and Community Based Organization (CBO)" Interface report.

To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.

To improve use of antibiotics in outpatient settings, where most prescribing occurs, by providing antibiotic stewardship resources for state health departments and state Medicaid agencies.

To provide laboratory support for the analysis of immunogenicity and shedding of new oral Poliovirus vaccines in human clinical trials and related issues for polio endgame.

To support efforts to strengthen and expand existing infection prevention control activities in various countries across Sub-Saharan Africa.

To evaluate the efficacy of injectable pre-exposure prophylaxis (PrEP) in HIV-uninfected populations.

To investigate other novel interventions, such as monoclonal antibodies (MAbs) against malaria. An intervention that could prevent malaria in children for a full 12 months in settings of perennial malaria transmission, such as Kenya, holds potential to reduce malaria morbidity and mortality substantially in this population at risk for severe malaria and death.

To support the chemistry, manufacturing and control (CMC) and preclinical development of an inactivated rotavirus vaccine.

To increase public awareness of water, sanitation and hygiene (WASH) issues and improve conditions in communities experiencing limited access or unsafe water systems in the United States.

To continue to increase health security in countries by improving their capacity and expanding support using new and more relevant tools of the National Action Plan for Health Security (NAPHS) Toolkit in at least six countries.

To maintain, produce, authenticate and distribute arthropod vectors and associated reagents for the Emerging Infections Resources Program.

To provide support to CDC, working toward the elimination of healthcare-associated infections in all medical care settings.